Implications of HIV PrEP trials results

Fulvia Veronese, Peter Anton, Courtney V Fletcher, Victor DeGruttola, Ian McGowan, Stephen Becker, Sheryl Zwerski, David Burns

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Six randomized clinical trials have been implemented to examine the efficacy of tenofovir disoproxil fumarate (TDF) and/or TDF/emtricitabine (TDF/FTC) as preexposure prophylaxis for HIV-1 infection (PrEP). Although largely complementary, the six trials have many similar features. As the earliest results become available, an urgent question may arise regarding whether changes should be made in the conduct of the other trials. To consider this in advance, a Consultation on the Implications of HIV Pre-Exposure Prophylaxis (PrEP) Trials Results sponsored by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and the Bill and Melinda Gates Foundation (BMGF) was held on January 29, 2010, at the Natcher Conference Center, NIH, Bethesda, MD. Participants included basic scientists, clinical researchers (including investigators performing the current PrEP trials), and representatives from the U.S. Food and Drug Administration (FDA) and the agencies sponsoring the trials: the U.S. Centers for Disease Control and Prevention (CDC), the U.S. Agency for International Development (USAID), the BMGF, and the U.S. NIH. We report here a summary of the presentations and highlights of salient discussion topics from this workshop.

Original languageEnglish (US)
Pages (from-to)81-90
Number of pages10
JournalAIDS Research and Human Retroviruses
Volume27
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

Tenofovir
National Institutes of Health (U.S.)
HIV
National Institute of Allergy and Infectious Diseases (U.S.)
United States Agency for International Development
Research Personnel
United States Food and Drug Administration
Centers for Disease Control and Prevention (U.S.)
HIV Infections
HIV-1
Acquired Immunodeficiency Syndrome
Referral and Consultation
Randomized Controlled Trials
Education
Pre-Exposure Prophylaxis

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Veronese, F., Anton, P., Fletcher, C. V., DeGruttola, V., McGowan, I., Becker, S., ... Burns, D. (2011). Implications of HIV PrEP trials results. AIDS Research and Human Retroviruses, 27(1), 81-90. https://doi.org/10.1089/aid.2010.0226

Implications of HIV PrEP trials results. / Veronese, Fulvia; Anton, Peter; Fletcher, Courtney V; DeGruttola, Victor; McGowan, Ian; Becker, Stephen; Zwerski, Sheryl; Burns, David.

In: AIDS Research and Human Retroviruses, Vol. 27, No. 1, 01.01.2011, p. 81-90.

Research output: Contribution to journalArticle

Veronese, F, Anton, P, Fletcher, CV, DeGruttola, V, McGowan, I, Becker, S, Zwerski, S & Burns, D 2011, 'Implications of HIV PrEP trials results', AIDS Research and Human Retroviruses, vol. 27, no. 1, pp. 81-90. https://doi.org/10.1089/aid.2010.0226
Veronese F, Anton P, Fletcher CV, DeGruttola V, McGowan I, Becker S et al. Implications of HIV PrEP trials results. AIDS Research and Human Retroviruses. 2011 Jan 1;27(1):81-90. https://doi.org/10.1089/aid.2010.0226
Veronese, Fulvia ; Anton, Peter ; Fletcher, Courtney V ; DeGruttola, Victor ; McGowan, Ian ; Becker, Stephen ; Zwerski, Sheryl ; Burns, David. / Implications of HIV PrEP trials results. In: AIDS Research and Human Retroviruses. 2011 ; Vol. 27, No. 1. pp. 81-90.
@article{24c9d063f9ef4e86b361d813061ab23c,
title = "Implications of HIV PrEP trials results",
abstract = "Six randomized clinical trials have been implemented to examine the efficacy of tenofovir disoproxil fumarate (TDF) and/or TDF/emtricitabine (TDF/FTC) as preexposure prophylaxis for HIV-1 infection (PrEP). Although largely complementary, the six trials have many similar features. As the earliest results become available, an urgent question may arise regarding whether changes should be made in the conduct of the other trials. To consider this in advance, a Consultation on the Implications of HIV Pre-Exposure Prophylaxis (PrEP) Trials Results sponsored by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and the Bill and Melinda Gates Foundation (BMGF) was held on January 29, 2010, at the Natcher Conference Center, NIH, Bethesda, MD. Participants included basic scientists, clinical researchers (including investigators performing the current PrEP trials), and representatives from the U.S. Food and Drug Administration (FDA) and the agencies sponsoring the trials: the U.S. Centers for Disease Control and Prevention (CDC), the U.S. Agency for International Development (USAID), the BMGF, and the U.S. NIH. We report here a summary of the presentations and highlights of salient discussion topics from this workshop.",
author = "Fulvia Veronese and Peter Anton and Fletcher, {Courtney V} and Victor DeGruttola and Ian McGowan and Stephen Becker and Sheryl Zwerski and David Burns",
year = "2011",
month = "1",
day = "1",
doi = "10.1089/aid.2010.0226",
language = "English (US)",
volume = "27",
pages = "81--90",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Implications of HIV PrEP trials results

AU - Veronese, Fulvia

AU - Anton, Peter

AU - Fletcher, Courtney V

AU - DeGruttola, Victor

AU - McGowan, Ian

AU - Becker, Stephen

AU - Zwerski, Sheryl

AU - Burns, David

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Six randomized clinical trials have been implemented to examine the efficacy of tenofovir disoproxil fumarate (TDF) and/or TDF/emtricitabine (TDF/FTC) as preexposure prophylaxis for HIV-1 infection (PrEP). Although largely complementary, the six trials have many similar features. As the earliest results become available, an urgent question may arise regarding whether changes should be made in the conduct of the other trials. To consider this in advance, a Consultation on the Implications of HIV Pre-Exposure Prophylaxis (PrEP) Trials Results sponsored by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and the Bill and Melinda Gates Foundation (BMGF) was held on January 29, 2010, at the Natcher Conference Center, NIH, Bethesda, MD. Participants included basic scientists, clinical researchers (including investigators performing the current PrEP trials), and representatives from the U.S. Food and Drug Administration (FDA) and the agencies sponsoring the trials: the U.S. Centers for Disease Control and Prevention (CDC), the U.S. Agency for International Development (USAID), the BMGF, and the U.S. NIH. We report here a summary of the presentations and highlights of salient discussion topics from this workshop.

AB - Six randomized clinical trials have been implemented to examine the efficacy of tenofovir disoproxil fumarate (TDF) and/or TDF/emtricitabine (TDF/FTC) as preexposure prophylaxis for HIV-1 infection (PrEP). Although largely complementary, the six trials have many similar features. As the earliest results become available, an urgent question may arise regarding whether changes should be made in the conduct of the other trials. To consider this in advance, a Consultation on the Implications of HIV Pre-Exposure Prophylaxis (PrEP) Trials Results sponsored by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and the Bill and Melinda Gates Foundation (BMGF) was held on January 29, 2010, at the Natcher Conference Center, NIH, Bethesda, MD. Participants included basic scientists, clinical researchers (including investigators performing the current PrEP trials), and representatives from the U.S. Food and Drug Administration (FDA) and the agencies sponsoring the trials: the U.S. Centers for Disease Control and Prevention (CDC), the U.S. Agency for International Development (USAID), the BMGF, and the U.S. NIH. We report here a summary of the presentations and highlights of salient discussion topics from this workshop.

UR - http://www.scopus.com/inward/record.url?scp=78651430243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651430243&partnerID=8YFLogxK

U2 - 10.1089/aid.2010.0226

DO - 10.1089/aid.2010.0226

M3 - Article

VL - 27

SP - 81

EP - 90

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 1

ER -